Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14.Invest with ...

Cytokinetics, Incorporated has announced the enrollment opening for AMBER-HFpEF, a Phase 2 randomized, placebo-controlled clinical trial evaluating the safety and tolerability of CK-586 in ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability ...

“We are pleased to be advancing CK-586 into a Phase 2 trial in a subset of patients with symptomatic HFpEF,” said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart ...